Liposomal amphotericin B and leishmaniasis: Dose and response
Open accessAbstract
Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
One currently approved nano-system (an amphotericin B liposomal formulation) is not cost-effective in developing countries.
“However, one currently approved nano-system (an amphotericin B liposomal formulation) is not cost-effective in developing countries 140 .”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 780 · see citing works
Self-citationTropical Infectious Diseases: Principles, Pathogens, and Practice
White, A. C., Atmar, R. L., & Greenberg, S. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00025 · Cited by 583 · see citing works
Injectable Paromomycin for Visceral Leishmaniasis in India
Sundar, S., Jha, T. K., Thakur, C. P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066536 · Cited by 471 · see citing works
Self-citationSingle-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 436 · see citing works
Self-citationWalsh, T. J., Goodman, J. L., Pappas, P. G., Bekersky, I., Buell, D. N., Roden, M. M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401 · see citing works
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 320 · see citing works
Meyerhoff, A. (1999) · Clinical Infectious Diseases · doi:10.1086/515085 · Cited by 296 · see citing works
Report of a WHO Expert Committee
NATORI, M. (1986) · Journal of Environmental Conservation Engineering · doi:10.5956/jriet.15.734 · Cited by 291 · see citing works
Risk Factors for Kala-Azar in Bangladesh
Bern, C., Hightower, A. W., Chowdhury, R., Ali, M., Amann, J., Wagatsuma, Y., Haque, R., Kurkjian, K. M., Vaz, L. E., Begum, M., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1105.040718 · Cited by 213 · see citing works
Sundar, S., Rai, M., Chakravarty, J., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/591972 · Cited by 209 · see citing works
Self-citationLiposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial
Davidson, R. N., di Martino, L., Gradoni, L., Giacchino, R., RUSSO, R., Gaeta, G. B., Pempinello, R., Scott, S., Raimondi, F., Cascio, A., et al. (1994) · QJM · doi:10.1093/oxfordjournals.qjmed.a068903 · Cited by 196 · see citing works
Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations
Sundar, S., Mehta, H., Suresh, A. V., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380971 · Cited by 189 · see citing works
Self-citationControl of the leishmaniases. Report of a WHO Expert Committee.
(1990) · PubMed · Cited by 178 · see citing works
Chunge, C. N., Owate, J., Pamba, H. O., et al. (1990) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(90)90263-e · Cited by 175 · see citing works
Berman, J. D., Badaró, R. J. D. S., Thakur, C. P., et al. (1998) · PubMed · Cited by 168 · see citing works
Sundar, S., Lockwood, D. N. J., Agrawal, G. K., et al. (2001) · BMJ · doi:10.1136/bmj.323.7310.419 · Cited by 165 · see citing works
Self-citationShort-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)
Davidson, R. N., di Martino, L., Gradoni, L., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.6.938 · Cited by 163 · see citing works
A PHASE II DOSE-INCREASING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN KENYA
Wasunna, M. K., RASHID, J. R., Mbui, J., et al. (2005) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2005.73.871 · Cited by 150 · see citing works
Addy, M., & Nandy, A. (1992) · PubMed · Cited by 137 · see citing works
Lee, J. W., Amantea, M., Francis, P. A., Navarro, E. E., Bacher, J. D., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.713 · Cited by 134 · see citing works
Sundar, S., Jha, T. K., Thakur, C. P., Mishra, M., Singh, V. P., & Buffels, R. (2003) · Clinical Infectious Diseases · doi:10.1086/377542 · Cited by 134 · see citing works
Self-citationSeaman, J., Pryce, D. H., Sondorp, H. E., et al. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.3.715 · Cited by 126 · see citing works
Response to Interferon‐γ plus Pentavalent Antimony in Indian Visceral Leishmaniasis
Sundar, S., Singh, V. P., Sharma, S., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/516526 · Cited by 116 · see citing works
Self-citationLiposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions
Seaman, J., Boer, C., Wilkinson, R. J., et al. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.188 · Cited by 110 · see citing works
Thakur, C. P., Kumar, M., Kumar, P., et al. (1988) · BMJ · doi:10.1136/bmj.296.6636.1557 · Cited by 103 · see citing works
Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
Sundar, S., Jha, T. K., Thakur, C. P., et al. (2002) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2002.66.143 · Cited by 99 · see citing works
Self-citationThakur, C. P., Pandey, A. K., Sinha, G. P., et al. (1996) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(96)90271-0 · Cited by 97 · see citing works
Russo, R., Nigro, L., Minniti, S., et al. (1996) · Journal of Infection · doi:10.1016/s0163-4453(96)91343-2 · Cited by 95 · see citing works
López‐Vélez, R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh084 · Cited by 95 · see citing works
Thakur, C. P., Olliaro, P., Gothoskar, S. V., et al. (1992) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(92)90150-b · Cited by 94 · see citing works
Syriopoulou, V., Daikos, G. L., Theodoridou, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/367843 · Cited by 87 · see citing works
Treatment of visceral leishmaniasis
Sundar, S., & Rai, M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.16.2821 · Cited by 87 · see citing works
Self-citationChanging response to diamidine compounds in cases of kala-azar unresponsive to antimonial.
Sn, J., Singh, N. K., & Tk, J. (1991) · PubMed · Cited by 84 · see citing works
Treatment of leishmaniasis in HIV-positive patients
Laguna, F. (2003) · Annals of Tropical Medicine and Parasitology · doi:10.1179/000349803225002606 · Cited by 78 · see citing works
Comparison of regimens of treatment with sodium stibogluconate in kala-azar.
Thakur, C. P., Kumar, M., Singh, S. K., et al. (1984) · BMJ · doi:10.1136/bmj.288.6421.895 · Cited by 75 · see citing works
Treatment of visceral leishmaniasis in children with liposomal amphotericin B
di Martino, L., Davidson, R. N., Giacchino, R., et al. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70165-3 · Cited by 73 · see citing works
The leishmaniases. Report of a WHO Expert Committee.
(1984) · PubMed · Cited by 70 · see citing works
Torre‐Cisneros, J., Villanueva, J., Kindelán, J. M., et al. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.625 · Cited by 68 · see citing works
Berenguer, J., Cosín, J., Miralles, P., et al. (2000) · AIDS · doi:10.1097/00002030-200012220-00020 · Cited by 67 · see citing works
Thakur, C. P. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00312-5 · Cited by 61 · see citing works
Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis, D. A., Velissariou, I. M., Stabouli, S., et al. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.09.011 · Cited by 59 · see citing works
Molina, I., Falcó, V., Casal, M. C., Riera, C., Ribera, E., Curran, A., Carrió, J., Diaz, M., del Saz, S. V., Fisa, R., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm294 · Cited by 56 · see citing works
Pentamidine-induced diabetes mellitus
Jha, T. K., & Sharma, V. (1984) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(84)90289-x · Cited by 50 · see citing works
Effect of tissue penetration on AmBisome efficacy.
Adler‐Moore, J., & Proffitt, R. T. (2003) · PubMed · Cited by 48 · see citing works
[Treatment of visceral leishmaniasis].
CARMONA, M. D. (1954) · PubMed · Cited by 47 · see citing works
Olliaro, P., & Sundar, S. (2008) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2008.02195.x · Cited by 40 · see citing works
Self-citationAmphotericin B for second-line treatment of Indian kala-azar
Mishra, M., Singh, M. P., Choudhury, D. C. R., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)90268-t · Cited by 39 · see citing works
A PHASE II DOSE-RANGING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN INDIA
JHA, T. K., SUNDAR, S., THAKUR, C. P., et al. (2005) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2005.73.1005 · Cited by 32 · see citing works
Self-citationLazanas, M. C., Tsekes, C. A., Papandreou, S., et al. (1993) · AIDS · doi:10.1097/00002030-199307000-00020 · Cited by 26 · see citing works
Montana, M., Chochoi, N., Monges, P., et al. (2004) · Pathologie Biologie · doi:10.1016/j.patbio.2003.09.012 · Cited by 23 · see citing works
Laguna, F., Torre‐Cisneros, J., Moreno, V., et al. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.3.711 · Cited by 19 · see citing works
[Childhood Mediterranean visceral leishmaniasis].
Cascio, A., & Colomba, C. (2003) · PubMed · Cited by 15 · see citing works
TREATMENT OF VISCERAL LEISHMANIASIS
Ozsoylu, S. N. (2003) · Pediatric Hematology and Oncology · doi:10.1080/08880010600642810 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597 · see citing works
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520 · see citing works
- Authors
- Sundar, S., & Chakravarty, J.
- Affiliations
- Institute of Medical Sciences (IN)
- Corresponding author
- Sundar, Shyam
- Venue
- Journal of Global Infectious Diseases
- Published
- 2010
- Volume
- 2
- Issue
- 2
- Pages
- 159
- ISSN
- 0974-777X (ISSN-L)
- PMC
- PMC2889656
- OpenAlex
- W2090009771
- Cited by
- 217
- References
- 53
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 24 · 2023: 30 · 2022: 17 · 2021: 18 · 2020: 18 · 2019: 20 · 2018: 9 · 2017: 12 · 2016: 11 · 2015: 4 · 2014: 8 · 2013: 7 · 2012: 5
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Global Infectious Diseases (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Allergy and Infectious Diseases (P50AI074321, U19AI074321)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Research on Leishmaniasis Studies
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Leprosy Research and Treatment
- Keywords
- liposomal amphotericin B, visceral leishmaniasis, treatment dose, secondary prophylaxis, combination therapy, short-course treatment, drug sensitivity, immunocompetent patient, Mediterranean
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
